May 10, 2007 (Las Vegas) — Rituximab can be safely infused using a rapid 90-minute protocol in patients with non-Hodgkin's lymphoma, according to a presentation made at the annual meeting of the ...

No patient in the 6-month rituximab group relapsed during the 24-month follow-up, and 1 patient in the 12-month group had a minor relapse. Tailored, risk-stratified rituximab regimens including yearly ...

Please provide your email address to receive an email when new articles are posted on . The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically ...

A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past ...

Medicare Part B (medical insurance) may cover Rituxan (rituximab) infusions. This is because medical professionals typically administer the medication in a medical setting on an outpatient basis.

Please provide your email address to receive an email when new articles are posted on . Research shows nearly 20% of patients with pemphigus experience relapse. An additional dose of rituximab in ...

Dr. Ellen Romich examines associated vasculitis relapse and which markers signal flare after stopping treatment.

Longitudinal study of anti-myeloma treatment patterns in a U.S. commercial population before and after approval of bortezomib (BOR). The utility and prognostic value of positron emission tomography ...

THOUSAND OAKS, Calif., June 6, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® ...

Last month, a retrospective observational study was published in PLOS One that investigated the safety and efficacy of rituximab in patients with progressive MS (PMS) and relapsing-remitting MS (RRMS) ...

The subcutaneous injection is for the treatment of follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. The Food and Drug Administration (FDA) has approved Rituxan ...